Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • American Society of Hematology

    - PMLiVE

    Preparing for ASH 2025: Pharma’s role in hematology innovation

    As the global hematology community prepares for the 67th ASH® Annual Meeting and Exposition, Inizio experts share their perspectives on what’s driving the field forward – and how pharma companies...

    Inizio

    - PMLiVE

    J&J presents positive phase 3 results for Darzalex Faspro in smouldering multiple myeloma

    The early precursor of active disease accounts for 15% of all newly-diagnosed multiple myeloma cases

    - PMLiVE

    Roche announces five-year results for Polivy combination in diffuse large B-cell lymphoma

    Approximately 160,000 cases of the aggressive blood cancer are diagnosed globally every year

    - PMLiVE

    Sanofi’s rilzabrutinib shows promise in phase 3 immune thrombocytopenia study

    Approximately 9.5 per 100,000 people in the US are affected by the rare autoimmune disorder

    regeneron headquarters

    Regeneron shares positive late-stage results for poze-cemdi in rare blood disorder PNH

    Paroxysmal nocturnal haemoglobinuria affects up to 1.5 people per million in the US

    - PMLiVE

    Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting

    The company will present 90 abstracts from across a wide range of haematologic diseases, including results from three pivotal studies in lymphoma and haemophilia

    - PMLiVE

    Mixed news for gene therapies at ASH conference

    GSK unveils successful trial, but there was disappointing news for Bluebird

    - PMLiVE

    Novel therapies for blood cancers showcased at ASH

    Novartis' lead CAR-T therapy is one of those in the spotlight

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links